CALLITAS HEALTH INC. ANNOUNCES FIRST CLOSING OF PRIVATE PLACEMENT

CINCINNATI, OH, USA (April 13, 2018) – **Callitas Health Inc.** (CSE: LILY, OTCBB: MPHMF, FWB: T3F2), (the "Company" or "Callitas") a clinical-stage company developing innovative technologies for weight management and female health and wellness, today announced that it has completed its first closing of a non-brokered private placement of convertible debenture units resulting in a total of $157,000 of convertible debenture units being issued. The debentures bear interest of 10% per annum for a term of 2 years, and are convertible into common shares of the Company at a conversion price of $0.50 per share. The Units consist of $500 in shares at $0.25 (2,000 shares), $500 unsecured debentures and 2,000 warrants at $0.32 for 2 years. Interest on the debentures will be pre-paid by the issuance of 400 common shares at a deemed price of $0.25 per share. In addition, finders' fees of $6,160 and 20,944 finders' warrants, which have the same terms as the warrants issued as part of the Convertible Debenture Units, were issued. All securities issued on closing are restricted from trading until August 13, 2018.

Proceeds will be used for general administrative expenses and to further certain of its development projects.

The Company also announced that it has issued a total of 400,000 shares as partial consideration to two consultants. These shares are also subject to trading restrictions until August 13, 2018.

About Callitas Health

Formed in early 2015, **Callitas Health Inc.** is a clinical-stage company developing innovative technologies for obesity, weight management and female health & wellness. In addition to its recent acquisitions of **C-103**, a reformulation of Orlistat, **Extrinsa** and assets from 40J's LLC, the Company successfully launched **ToConceive** in North America as a clinically proven option for couples struggling with the inability to conceive. www.toconceive.com.

For more information contact:
James Thompson, CEO, or
Callitas Investor Relations
Phone: +1 (859) 868-3131
www.callitas.com

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval and the commercialization of the rights to the Company's biomedical & drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: CannaMint Strips, C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.